Know Cancer

forgot password

A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Phase 2
18 Years
Open (Enrolling)

Thank you

Trial Information

A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Inclusion Criteria:

- Patients must have histologically confirmed diagnosis of glioblastoma multiforme
(GBM), with recurrent or progressive disease following or during primary treatment
not curable with standard therapies.

- All patients must have formalin fixed paraffin embedded tissue available for
translational studies.

- Presence of bidimensionally measurable enhancing lesions on CT or MRI, with at least
one lesion with a minimum dimension of 1 cm x 1 cm (i.e. both dimensions must be ≥
1.0 cm). Baseline CT or MRI must be done within 14 days prior to registration.

- ECOG performance of 0, 1 or 2.

- Age ≥ 18 years of age. Previous Therapy


Patients may have received prior adjuvant chemotherapy and/or concurrent chemoradiation as
part of primary therapy, but must have received no therapy for recurrent/ progressive GBM
(i.e. PX-866 must be first treatment for recurrence/ progression). A minimum of 28 days
since the last dose of chemotherapy must have elapsed prior to registration.

Targeted Therapy:

No prior therapy with a phosphatidylinositol 3-kinase (PI-3K) inhibitor. Other targeted
agents are permissible provided they were given as part of front line treatment. A minimum
of 56 days (8 weeks) must have elapsed since last day for anti-angiogenic therapy and
minimum of 28 days for other targeted agents.


Patients may have had prior radiation therapy provided at least 28 days have elapsed from
the day of the last fraction of radiation to the date of registration.

- Previous Surgery: Previous surgery is permitted provided that wound healing has occurred
and at least 14 days have elapsed prior to registration.

5.1.7 Laboratory Requirements (must be done within 7 days prior to registration)


Granulocytes (AGC) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L


Serum creatinine ≤ 1.5 x UNL Total bilirubin ≤ 1.5 x UNL ALT and AST ≤ 1.5 x UNL Glucose ≤
8.9 mmol/L (≤ Grade 1)

- Women must be post menopausal, surgically sterile or use a reliable form of
contraception while on study and for 30 days after discontinuing therapy. Women of
childbearing potential must have a pregnancy test taken and proven negative within 7
days prior to registration and must not be lactating.

- Patient consent must be obtained according to local Institutional and/or University
Human Experimentation Committee requirements. It will be the responsibility of the
local participating investigators to obtain the necessary local clearance, and to
indicate in writing to the NCIC CTG Study Coordinator that such clearance has been
obtained, before the trial can commence in that centre. Because of differing
requirements, a standard consent form for the trial will not be provided but a sample
form is provided. A copy of the initial full board REB approval and approved consent
form must be sent to the central office. The patient must sign the consent form prior
to registration (exception for translations). Please note that the consent form for
this study must contain a statement which gives permission for the NCIC CTG and
monitoring agencies to review patient records Patients who cannot give informed
consent (i.e. mentally incompetent patients, or those physically incapacitated such
as comatose patients) are not to be recruited into the study. Patients competent but
physically unable to sign the consent form may have the document signed by their
nearest relative or legal guardian. Each patient will be provided with a full
explanation of the study before consent is requested.

- Patients must be accessible for treatment and follow-up. Patients registered on this
trial must be treated and followed at the participating centre. This implies there
must be reasonable geographical limits (for example: 2 hour's driving distance)
placed on patients being considered for this trial. Investigators must assure
themselves that the patients registered on this trial will be available for complete
documentation of the treatment, adverse events, response assessment and follow-up.

- In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working
days of patient registration.

Exclusion Criteria:

- Patients who have other active malignancies (i.e. documented by imaging, clinical
exam or marker) are to be excluded. (Please call NCIC CTG if any questions about the
interpretation of this criterion).

- Known HIV-positive patients.

- Uncontrolled diabetes mellitus.

- Patients should be on a stable dose of steroid (i.e. no change in dose for 2 weeks
prior to registration) when entered on study. Patients recently started on steroids
or whose steroid dose was increased in the recent past should not be started on
protocol treatment until at least 2 weeks have passed from the time of steroid dose
increment or initiation. Under these circumstances, baseline CT or MRI scan for
purposes of assessment of response to protocol treatment should be done at the time
of initiation of protocol therapy (i.e., these patients must be re-imaged to control
for steroid effects).


The idea behind this is to restrict entry to a subset of patients who are not rapidly
changing: especially rapidly deteriorating. If a patient being worked up for the trial
appears to need to have steroid introduced or increased, the patient should be treated as
is medically appropriate (i.e., have the steroid introduced or increased). Steroid should
NOT be withheld if clinically indicated just so that patients can be registered on study!

- Patients with upper gastrointestinal or other conditions that would preclude
compliance or absorption of oral medication are not eligible.

- Patients with active or uncontrolled infections, or with serious illnesses or medical
conditions which would not permit the patient to be managed according to the

- Patients are not eligible if they have a known hypersensitivity to the study drugs or
their components.

- Patients who have had prior treatment with a PI3 kinase inhibitor.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response and progression rates assessed by evaluation of change in product of bidimensional measurement of enhancing brain tumour on computed tomography (CT) scan or Magnetic Resonance Imaging (MRI)

Outcome Description:

Efficacy of PX-866 given orally daily in patients with glioblastoma at the time of first relapse or progression as assessed by objective response and early progression rates assessed by evaluation of change in product of bidimensional measurement of enhancing brain tumour on CT scan or MRI

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Marshall Pitz

Investigator Role:

Study Chair

Investigator Affiliation:

CancerCare Manitoba


Canada: Health Canada

Study ID:




Start Date:

January 2011

Completion Date:

December 2013

Related Keywords:

  • Glioblastoma
  • Glioblastoma